A heterozygous effect for PINK1 mutations in Parkinson's disease?
Objective To investigate the significance of PINK1 mutations in sporadic Parkinson's disease (PD). Methods We determined the frequency of PINK1 mutations by direct sequencing in a large series of PD patients with apparently sporadic disease (n = 768). Results Twelve heterozygous mutations were...
Saved in:
Published in | Annals of neurology Vol. 60; no. 4; pp. 414 - 419 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.10.2006
Willey-Liss |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Objective
To investigate the significance of PINK1 mutations in sporadic Parkinson's disease (PD).
Methods
We determined the frequency of PINK1 mutations by direct sequencing in a large series of PD patients with apparently sporadic disease (n = 768).
Results
Twelve heterozygous mutations were identified, nine in PD patients and three in control subjects.
Interpretation
Given the difficulty in interpreting the pathogenic significance of the heterozygous mutations that have already been reported in parkin and DJ‐1, we first determined the frequency of heterozygous PINK1 mutations in the general population by sequencing a large number of control subjects (n = 768), then subsequently assessed their functional significance by examining their effects on stress‐induced alterations to the mitochondrial membrane potential (ΔΨm). We demonstrate an enrichment of heterozygous mutations in sporadic PD patients compared with matched control subjects (1.2% in PD vs 0.4% in control subjects). Furthermore, we show that they adversely affect ΔΨm in a similar way to the familial G309D mutation. Although it remains difficult to conclusively demonstrate the pathogenicity of heterozygous mutations, the results of this study and the previously reported subclinical nigrostriatal dysfunction in carriers of heterozygous PINK1 mutations suggest the possibility that these heterozygous mutations are a significant risk factor in the development of later onset PD. Ann Neurol 2006 |
---|---|
Bibliography: | Parkinson's Disease Society, United Kingdom Medical Research Council (MRC) program - No. G0400000 Medical Research Council Clinical Research Training Fellowship ark:/67375/WNG-287X9187-N Brain Research Trust istex:6CE7C459FEF8A961BD4D38267460919D919D227F ArticleID:ANA20960 Wellcome Trust Research Training Fellowship ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0364-5134 1531-8249 |
DOI: | 10.1002/ana.20960 |